PMID- 15643180
OWN - NLM
STAT- MEDLINE
DCOM- 20050303
LR  - 20061115
IS  - 0022-5347 (Print)
IS  - 0022-5347 (Linking)
VI  - 173
IP  - 2
DP  - 2005 Feb
TI  - Monitoring intravesical therapy for superficial bladder cancer using fluorescence 
      in situ hybridization.
PG  - 401-4
AB  - PURPOSE: We evaluated fluorescence in situ hybridization (FISH) for assessing the 
      response to therapy in patients with superficial bladder cancer receiving 
      bacillus Calmette-Guerin or other intravesical therapies. MATERIALS AND METHODS: 
      A total of 37 patients receiving intravesical therapy for superficial bladder 
      cancer were enrolled in this study. Urine specimens were collected for FISH 
      analysis just prior to the first intravesical therapy in 31 cases and just prior 
      to or within 2 months following the last intravesical therapy in 37. FISH was 
      done using the UroVysion probe set (Abbott Laboratories, Abbott Park, Illinois) 
      with results considered positive if 5 or more cells demonstrated polysomy. 
      Biopsy, cystoscopy and/or cytology results were then compared to FISH results to 
      evaluate the usefulness of the test for monitoring intravesical therapy. RESULTS: 
      Of the patients 25 had a negative and 12 had a positive post-therapy FISH result. 
      All 12 patients with a positive post-therapy FISH result had tumor recurrence, 
      while tumor recurrence was observed in 13 of the 25 with a negative post-therapy 
      FISH result (HR 4.6, 95% CI 1.9 to 11.1, p <0.001). Of the patients with tumor 
      recurrence 7 of 12 with a positive post-therapy FISH result had muscle invasive 
      tumor and 2 of 25 with a negative post-therapy FISH result had muscle invasive 
      tumor (HR 9.4, 95% CI 1.9 to 45.3, p = 0.001). CONCLUSIONS: FISH appears to be 
      useful for monitoring patients with superficial bladder cancer for the response 
      to intravesical therapy. Patients with a positive FISH result at the end of 
      treatment are at high risk for progression to muscle invasive bladder cancer.
FAU - Kipp, Benjamin R
AU  - Kipp BR
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, 
      Rochester, Minnesota 55905, USA.
FAU - Karnes, R Jeffrey
AU  - Karnes RJ
FAU - Brankley, Shannon M
AU  - Brankley SM
FAU - Harwood, Aaron R
AU  - Harwood AR
FAU - Pankratz, V Shane
AU  - Pankratz VS
FAU - Sebo, Thomas J
AU  - Sebo TJ
FAU - Blute, Michael M
AU  - Blute MM
FAU - Lieber, Michael M
AU  - Lieber MM
FAU - Zincke, Horst
AU  - Zincke H
FAU - Halling, Kevin C
AU  - Halling KC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (BCG Vaccine)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Administration, Intravesical
MH  - Aged
MH  - Aged, 80 and over
MH  - BCG Vaccine/*administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Urinary Bladder Neoplasms/*drug therapy/*pathology
EDAT- 2005/01/12 09:00
MHDA- 2005/03/04 09:00
CRDT- 2005/01/12 09:00
PHST- 2005/01/12 09:00 [pubmed]
PHST- 2005/03/04 09:00 [medline]
PHST- 2005/01/12 09:00 [entrez]
AID - S0022-5347(05)60475-2 [pii]
AID - 10.1097/01.ju.0000149825.83180.a4 [doi]
PST - ppublish
SO  - J Urol. 2005 Feb;173(2):401-4. doi: 10.1097/01.ju.0000149825.83180.a4.